BIOA BIOAGE LABS INC.

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

• Jefferies Global Healthcare Conference (New York, June 3–5, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, will participate in one-on-one meetings.

• Goldman Sachs 46th Annual Global Healthcare Conference (Miami, June 9–11, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, June 9, 2025 at 3:20–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register .

Replays of the webcasts will be available in the investor section of the company's website at , and will be archived for 30 days following the presentations.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts

PR: Chris Patil,

IR: Dov Goldstein,

Partnering:

Web:



EN
27/05/2025

Underlying

BIOABIOAGE LABS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOAGE LABS INC.

 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Scie...

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026. Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday,...

February 19, 2026 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

BioAge Announces Pricing of Upsized $115.0 Million Public Offering EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting und...

January 22, 2026 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Announces Proposed Public Offering

BioAge Announces Proposed Public Offering EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwriters a 30-day option to purchase up to an additional $1...

January 20, 2026 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102...

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic macular edema (DME) BGE-102 has demonstrated favorable tolera...

January 20, 2026 1 EN
 PRESS RELEASE
Free
BIOA BIOAGE LABS INC...

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102,...

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels (3 mg/L), BGE-102 120 mg once daily achieved an 86% median reduction in high-sensitivity C-reactive protein (h...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch